ALD
MCID: ADR007
MIFTS: 71

Adrenoleukodystrophy (ALD)

Categories: Endocrine diseases, Genetic diseases, Metabolic diseases, Neuronal diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Adrenoleukodystrophy

MalaCards integrated aliases for Adrenoleukodystrophy:

Name: Adrenoleukodystrophy 58 39 12 77 54 55 76 38 30 13 56 6 45 15 41 74
X-Linked Adrenoleukodystrophy 12 77 25 54 26 60
Ald 58 12 54 60 76
Siemerling-Creutzfeldt Disease 58 12 26 76
Addison Disease and Cerebral Sclerosis 58 26 76
Melanodermic Leukodystrophy 58 26 76
Bronze Schilder Disease 58 12 76
Adrenomyeloneuropathy 60 76 74
X-Ald 54 26 60
Diffuse Cerebral Sclerosis of Schilder 12 74
Schilder's Disease 12 55
Diffuse Sclerosis 12 55
Schilder Disease 12 26
X-Linked Cerebral Adrenoleukodystrophy 60
Encephalitis Periaxialis Concentrica 12
Encephalitis Periaxialis, Schilder's 12
Sudanophilic Cerebral Sclerosis 12
Adrenoleukodystrophy, X-Linked 77
Adrenomyeloneuropathy, Adult 58
Balo's Concentric Sclerosis 74
Schilder-Addison Complex 26
Systemic Scleroderma 74
X-Linked Ald 60
X-Cald 60
Amn 76

Characteristics:

Orphanet epidemiological data:

60
x-linked adrenoleukodystrophy
Inheritance: X-linked recessive; Prevalence: 1-9/100000 (Worldwide),1-9/100000 (Europe); Age of onset: All ages;
x-linked cerebral adrenoleukodystrophy
Inheritance: X-linked recessive; Age of onset: All ages;
adrenomyeloneuropathy
Inheritance: X-linked recessive; Age of onset: Adult;

OMIM:

58
Miscellaneous:
progressive disorder
highly variable phenotype, ranging from asymptomatic to death by age 3 years
onset ranges from childhood (severe phenotype) to adulthood (limited phenotype)
heterozygous female carriers may manifest symptoms
estimated incidence of 1 in 17,000

Inheritance:
x-linked recessive


HPO:

33
adrenoleukodystrophy:
Onset and clinical course progressive
Inheritance x-linked inheritance x-linked recessive inheritance


Classifications:



Summaries for Adrenoleukodystrophy

NINDS : 55 X-linked Adrenoleukodystrophy (ALD) is one of a group of genetic disorders called the leukodystrophies that cause damage to the myelin sheath, an insulating membrane that surrounds nerve cells in the brain. Women have two X chromosomes and are the carriers of the disease, but since men only have one X chromosome and lack the protective effect of the extra X chromosome, they are more severely affected.  People with X-ALD accumulate high levels of saturated, very long chain fatty acids (VLCFA) in the brain and adrenal cortex. The loss of myelin and the progressive dysfunction of the adrenal gland are the primary characteristics of X-ALD. While nearly all patients with X-ALD suffer from adrenal insufficiency, also known as Addison's disease, the neurological symptoms can begin either in childhood or in adulthood. The childhood cerebral form is the most severe, with onset between ages 4 and 10. The most common symptoms are usually behavioral changes such as abnormal withdrawal or aggression, poor memory, and poor school performance. Other symptoms include visual loss, learning disabilities, seizures, poorly articulated speech, difficulty swallowing, deafness, disturbances of gait and coordination, fatigue, intermittent vomiting, increased skin pigmentation, and progressive dementia. The milder adult-onset form is also known as adrenomyeloneuropathy (AMN), which typically begins between ages 21 and 35.  Symptoms may include progressive stiffness, weakness or paralysis of the lower limbs, and ataxia. Although adult-onset ALD progresses more slowly than the classic childhood form, it can also result in deterioration of brain function. Almost half the women who are carriers of X-ALS will develop a milder form of AMN; such carriers almost never develop symptoms that are seen in boys the X-ALD.  X-ALD should not be confused with neonatal adrenoleukodsystrophy, which is a disease of newborns and young infants and belongs to the group of peroxisomal biogenesis disorders.

MalaCards based summary : Adrenoleukodystrophy, also known as x-linked adrenoleukodystrophy, is related to peroxisomal acyl-coa oxidase deficiency and peroxisome biogenesis disorder 1a, and has symptoms including seizures, ataxia and pruritus. An important gene associated with Adrenoleukodystrophy is ABCD1 (ATP Binding Cassette Subfamily D Member 1), and among its related pathways/superpathways are ABC transporters and Peroxisome. The drugs Prednisolone phosphate and Methylprednisolone have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and adrenal cortex, and related phenotypes are intellectual disability and gait disturbance

Disease Ontology : 12 A leukodystrophy that disrupts the breakdown of very-long-chain fatty acids resulting in progressive brain damage, failure of the adrenal glands and eventually death.

Genetics Home Reference : 26 X-linked adrenoleukodystrophy is a genetic disorder that occurs primarily in males. It mainly affects the nervous system and the adrenal glands, which are small glands located on top of each kidney. In this disorder, the fatty covering (myelin) that insulates nerves in the brain and spinal cord is prone to deterioration (demyelination), which reduces the ability of the nerves to relay information to the brain. In addition, damage to the outer layer of the adrenal glands (adrenal cortex) causes a shortage of certain hormones (adrenocortical insufficiency). Adrenocortical insufficiency may cause weakness, weight loss, skin changes, vomiting, and coma.

NIH Rare Diseases : 54 X-linked adrenoleukodystrophy (X-ALD) is a genetic disease that affects the nervous system and the adrenal glands (small glands located on top of each kidney). People with this disease often have progressive loss of the fatty covering (myelin) that surrounds the nerves in the brain and spinal cord. They may also have a shortage of certain hormones that is caused by damage to the outer layer of the adrenal glands (adrenal cortex). This is called adrenocortical insufficiency, or Addison disease. There are three forms of X-ALD: a childhood cerebral form, an adrenomyeloneuropathy (AMN) type, and an adrenal-insufficiency-only-type. The disease primarily affects males. X-ALD is caused by a variation (mutation) in the ABCD1 gene and it is inherited in an X-linked. manner. Diagnosis of the disease is based on testing the levels of a molecule called very long-chain fatty acids (VLCFA). The diagnosis can be confirmed with genetic testing. There is still no cure for X-ALD, but taking special oils such as Lorenzo�??s oil can lower the blood levels of VLCFA. Bone marrow transplantation may be an option for boys who have evidence of brain involvement on MRI, but do not yet have obvious symptoms of the disease with a normal neurological exam. Adrenocortical insufficiency is treated with corticosteroids. 

OMIM : 58 Adrenoleukodystrophy is an X-linked disorder which is secondary to a mutation in the ABCD1 gene and results in the apparent defect in peroxisomal beta oxidation and the accumulation of the saturated very long chain fatty acids (VLCFA) in all tissues of the body. The manifestations of the disorder occur primarily in the adrenal cortex, the myelin of the central nervous system, and the Leydig cells of the testes. ABCD1 is an ATPase binding cassette protein in the same category of transporter proteins such as the CFTR and MDR proteins. Identification of X-ALD as a lipid-storage disease, as a defect in the capacity to degrade VLCFAs, and its characterization as a peroxisomal disorder was reviewed by Moser (1997). Moser et al. (2005) provided a clinical review of ALD. (300100)

UniProtKB/Swiss-Prot : 76 Adrenoleukodystrophy: A peroxisomal metabolic disorder characterized by progressive multifocal demyelination of the central nervous system and by peripheral adrenal insufficiency (Addison disease). It results in mental deterioration, corticospinal tract dysfunction, and cortical blindness. Different clinical manifestations exist like: cerebral childhood ALD (CALD), adult cerebral ALD (ACALD), adrenomyeloneuropathy (AMN) and 'Addison disease only' (ADO) phenotype.

Wikipedia : 77 Adrenoleukodystrophy (ALD) is a disease linked to the X chromosome. It is a result of fatty acid buildup... more...

GeneReviews:

Related Diseases for Adrenoleukodystrophy

Diseases related to Adrenoleukodystrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 184)
# Related Disease Score Top Affiliating Genes
1 peroxisomal acyl-coa oxidase deficiency 33.2 ACOX1 CAT PEX5
2 peroxisome biogenesis disorder 1a 32.5 PEX1 PEX10
3 zellweger spectrum disorder 32.0 PEX1 PEX10 PEX6
4 neonatal adrenoleukodystrophy 31.8 ACOX1 CAT EHHADH PEX1 PEX10 PEX19
5 peroxisome biogenesis disorder 1b 31.2 ABCD3 CAT PEX1 PEX10 PEX19 PEX26
6 d-bifunctional protein deficiency 31.0 ACOX1 CAT EHHADH PEX5
7 zellweger syndrome 30.2 ABCD3 EHHADH PEX1 PEX10 PEX19 PEX26
8 peroxisomal disease 30.1 ABCD1 CAT PEX1 PEX5
9 refsum disease, classic 30.0 CAT PEX5
10 rhizomelic chondrodysplasia punctata 29.7 PEX26 PEX5
11 childhood-onset cerebral x-linked adrenoleukodystrophy 12.6
12 megaloblastic anemia 1 12.2
13 adrenomyeloneuropathy 12.1
14 tumefactive multiple sclerosis 12.0
15 mitochondrial dna depletion syndrome 4a 11.7
16 pelizaeus-merzbacher disease 11.5
17 balo concentric sclerosis 11.5
18 megaloblastic anemia 11.5
19 leukodystrophy 11.4
20 peroxisome biogenesis disorder 4b 11.4
21 3-methylglutaconic aciduria, type i 11.3
22 vitamin b12 deficiency 11.3
23 albinism-deafness syndrome 11.3
24 donnai-barrow syndrome 11.2
25 vitamin metabolic disorder 11.2
26 congenital intrinsic factor deficiency 11.2
27 peroxisome biogenesis disorder 2b 11.1
28 peroxisome biogenesis disorder 3b 11.1
29 peroxisome biogenesis disorder 5b 11.1
30 peroxisome biogenesis disorder 6b 11.1
31 peroxisome biogenesis disorder 7b 11.1
32 peroxisome biogenesis disorder 11b 11.1
33 peroxisome biogenesis disorder 2a 10.9
34 sudanophilic cerebral sclerosis 10.9
35 peroxisome biogenesis disorder 3a 10.9
36 peroxisome biogenesis disorder 4a 10.9
37 peroxisome biogenesis disorder 5a 10.9
38 peroxisome biogenesis disorder 6a 10.9
39 peroxisome biogenesis disorder 7a 10.9
40 peroxisome biogenesis disorder 8a 10.9
41 peroxisome biogenesis disorder 8b 10.9
42 peroxisome biogenesis disorder 9b 10.9
43 peroxisome biogenesis disorder 10a 10.9
44 peroxisome biogenesis disorder 11a 10.9
45 peroxisome biogenesis disorder 12a 10.9
46 peroxisome biogenesis disorder 13a 10.9
47 peroxisome biogenesis disorder-zellweger syndrome spectrum 10.9
48 wells-jankovic syndrome 10.9
49 myelinoclastic diffuse sclerosis 10.9
50 spasticity 10.9

Graphical network of the top 20 diseases related to Adrenoleukodystrophy:



Diseases related to Adrenoleukodystrophy

Symptoms & Phenotypes for Adrenoleukodystrophy

Human phenotypes related to Adrenoleukodystrophy:

60 33 (show top 50) (show all 56)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 intellectual disability 60 33 hallmark (90%) Very frequent (99-80%) HP:0001249
2 gait disturbance 60 33 hallmark (90%) Very frequent (99-80%) HP:0001288
3 abnormality of metabolism/homeostasis 60 33 hallmark (90%) Very frequent (99-80%) HP:0001939
4 attention deficit hyperactivity disorder 60 33 hallmark (90%) Very frequent (99-80%) HP:0007018
5 specific learning disability 60 33 hallmark (90%) Very frequent (99-80%) HP:0001328
6 visual loss 60 33 hallmark (90%) Very frequent (99-80%) HP:0000572
7 dementia 60 33 hallmark (90%) Very frequent (99-80%) HP:0000726
8 headache 60 33 hallmark (90%) Very frequent (99-80%) HP:0002315
9 clumsiness 60 33 hallmark (90%) Very frequent (99-80%) HP:0002312
10 sensory impairment 60 33 hallmark (90%) Very frequent (99-80%) HP:0003474
11 progressive hearing impairment 60 33 hallmark (90%) Very frequent (99-80%) HP:0001730
12 functional motor deficit 60 33 hallmark (90%) Very frequent (99-80%) HP:0004302
13 progressive spastic paraparesis 60 33 hallmark (90%) Very frequent (99-80%) HP:0007199
14 leg muscle stiffness 60 33 hallmark (90%) Very frequent (99-80%) HP:0008969
15 increased intracranial pressure 60 33 frequent (33%) Frequent (79-30%) HP:0002516
16 urinary bladder sphincter dysfunction 60 33 frequent (33%) Frequent (79-30%) HP:0002839
17 visual field defect 60 33 frequent (33%) Frequent (79-30%) HP:0001123
18 aphasia 60 33 frequent (33%) Frequent (79-30%) HP:0002381
19 aggressive behavior 60 33 frequent (33%) Frequent (79-30%) HP:0000718
20 increased circulating acth level 60 33 frequent (33%) Frequent (79-30%) HP:0003154
21 disinhibition 60 33 frequent (33%) Frequent (79-30%) HP:0000734
22 hemiparesis 60 33 frequent (33%) Frequent (79-30%) HP:0001269
23 neurogenic bladder 60 33 frequent (33%) Frequent (79-30%) HP:0000011
24 adrenal insufficiency 60 33 frequent (33%) Frequent (79-30%) HP:0000846
25 inappropriate sexual behavior 60 33 frequent (33%) Frequent (79-30%) HP:0008768
26 diplopia 60 33 occasional (7.5%) Occasional (29-5%) HP:0000651
27 paralysis 60 33 occasional (7.5%) Occasional (29-5%) HP:0003470
28 impotence 60 33 occasional (7.5%) Occasional (29-5%) HP:0000802
29 incoordination 60 33 Very frequent (99-80%) HP:0002311
30 paraparesis 60 33 Very frequent (99-80%) HP:0002385
31 seizures 33 HP:0001250
32 bowel incontinence 33 HP:0002607
33 hearing impairment 33 HP:0000365
34 behavioral abnormality 60 Very frequent (99-80%)
35 visual impairment 60 Very frequent (99-80%)
36 blindness 33 HP:0000618
37 cognitive impairment 60 Very frequent (99-80%)
38 abnormality of vision 60 Very frequent (99-80%)
39 slurred speech 33 HP:0001350
40 limb ataxia 33 HP:0002070
41 abnormality of the skeletal system 33 HP:0000924
42 primary adrenal insufficiency 33 HP:0008207
43 hypogonadism 33 HP:0000135
44 psychosis 33 HP:0000709
45 neurodegeneration 33 HP:0002180
46 truncal ataxia 33 HP:0002078
47 spastic paraplegia 33 HP:0001258
48 urinary incontinence 33 HP:0000020
49 hyperactivity 60 Very frequent (99-80%)
50 polyneuropathy 33 HP:0001271

Symptoms via clinical synopsis from OMIM:

58
Neurologic Central Nervous System:
seizures
ataxia
spasticity
dementia
bulbar palsy
more
Genitourinary Bladder:
urinary incontinence

Head And Neck Ears:
hearing loss

Neurologic Peripheral Nervous System:
sensory loss
distal axonopathy (adrenomyeloneuropathy)

Endocrine Features:
adrenal insufficiency (addison disease)

Neurologic Behavioral Psychiatric Manifestations:
psychosis
autistic features
behavioral changes
attention deficit-hyperactivity disorder

Genitourinary External Genitalia Male:
impotence

Abdomen Gastrointestinal:
fecal incontinence

Head And Neck Eyes:
loss of vision

Laboratory Abnormalities:
systemic accumulation of very long chain fatty acids (vlcfa)

Clinical features from OMIM:

300100

UMLS symptoms related to Adrenoleukodystrophy:


seizures, ataxia, pruritus, paraparesis, exanthema, muscle spasticity, hidebound skin, absence of sensation, unspecified visual loss

MGI Mouse Phenotypes related to Adrenoleukodystrophy:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.36 ABCB6 ABCD1 ABCD2 ABCD3 ACOX1 CAT

Drugs & Therapeutics for Adrenoleukodystrophy

Drugs for Adrenoleukodystrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 101)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
2
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
3
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 3 50-18-0, 6055-19-2 2907
4
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
5
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 55-98-1 2478
6
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
7
Fludarabine Approved Phase 3,Phase 2,Phase 1 75607-67-9, 21679-14-1 30751
8
Glycerol Approved, Investigational Phase 2, Phase 3 56-81-5 753
9
Biotin Approved, Investigational, Nutraceutical Phase 2, Phase 3 58-85-5 171548
10
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
11
Betaine Approved, Nutraceutical Phase 3 107-43-7 247
12
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
13 Trace Elements Phase 2, Phase 3,Phase 1
14 Vitamin B7 Phase 2, Phase 3
15 Vitamin B Complex Phase 2, Phase 3
16 Vitamins Phase 2, Phase 3,Phase 1
17 Vitamin B9 Phase 2, Phase 3
18 Folate Phase 2, Phase 3
19 Nutrients Phase 2, Phase 3,Phase 1
20 Micronutrients Phase 2, Phase 3,Phase 1
21 Cholic Acids Phase 3,Not Applicable
22 Gastrointestinal Agents Phase 3,Not Applicable
23 Bile Acids and Salts Phase 3,Not Applicable
24 Liver Extracts Phase 3
25 Prednisolone acetate Phase 2, Phase 3
26 Antineoplastic Agents, Alkylating Phase 2, Phase 3,Phase 1,Not Applicable
27 Methylprednisolone Acetate Phase 2, Phase 3
28 Alkylating Agents Phase 2, Phase 3,Phase 1,Not Applicable
29 Immunologic Factors Phase 2, Phase 3,Phase 1,Not Applicable
30 Immunosuppressive Agents Phase 2, Phase 3,Phase 1,Not Applicable
31 Antilymphocyte Serum Phase 2, Phase 3,Phase 1
32 Antirheumatic Agents Phase 2, Phase 3,Not Applicable
33 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
34 Lipid Regulating Agents Phase 3,Not Applicable
35 Hypolipidemic Agents Phase 3,Not Applicable
36 Pharmaceutical Solutions Phase 3,Phase 2
37
Acetylcysteine Approved, Investigational Phase 2,Phase 1 616-91-1 12035
38
Tocopherol Approved, Investigational Phase 2 1406-66-2 14986
39
Benzocaine Approved, Investigational Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
40
Hydroxyurea Approved Phase 2 127-07-1 3657
41
Melphalan Approved Phase 2,Not Applicable 148-82-3 460612 4053
42
alemtuzumab Approved, Investigational Phase 2,Not Applicable 216503-57-0
43
Clofarabine Approved, Investigational Phase 2,Not Applicable 123318-82-1 119182
44
tannic acid Approved Phase 2,Not Applicable 1401-55-4
45
Miconazole Approved, Investigational, Vet_approved Phase 2,Not Applicable 22916-47-8 4189
46
Mycophenolic acid Approved Phase 2,Not Applicable 24280-93-1 446541
47
Mesna Approved, Investigational Phase 2 3375-50-6 598
48
Thiotepa Approved, Investigational Phase 2,Phase 1 52-24-4 5453
49
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
50
rituximab Approved Phase 2 174722-31-7 10201696

Interventional clinical trials:

(show all 46)
# Name Status NCT ID Phase Drugs
1 MD1003-AMN MD1003 in Adrenomyeloneuropathy Completed NCT02961803 Phase 2, Phase 3 MD1003 100 mg capsule;Placebo
2 Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid Completed NCT00007020 Phase 3 Cholic Acids
3 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
4 Betaine and Peroxisome Biogenesis Disorders Completed NCT01838941 Phase 3 Betaine
5 Clinical Study to Assess the Efficacy and Safety of Gene Therapy for the Treatment of Cerebral Adrenoleukodystrophy (CALD) Recruiting NCT03852498 Phase 3 Genetic
6 A Phase 2/3 Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD) Active, not recruiting NCT01896102 Phase 2, Phase 3
7 A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients. Active, not recruiting NCT03231878 Phase 2, Phase 3 MIN-102;Placebos
8 Effect of Glycerol Trierucate on Clinical Course of Adrenoleukodystrophy Suspended NCT00004418 Phase 2, Phase 3 glyceryl trierucate;glyceryl trioleate
9 A Phase III Trial of Lorenzo's Oil in Adrenomyeloneuropathy Terminated NCT00545597 Phase 3 Lorenzo's oil
10 ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases Terminated NCT00654433 Phase 3
11 A Clinical Trial for AMN: Validation of Biomarkers of Oxidative Stress, Efficacy and Safety of a Mixture of Antioxidants Completed NCT01495260 Phase 2 N-acetylcysteine;lipoic acid;vitamin E
12 HSCT for High Risk Inherited Inborn Errors Completed NCT00383448 Phase 2 Clofarabine;Melphalan;Alemtuzumab;mycophenylate mofetil;Hydroxyurea
13 Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders Completed NCT01043640 Phase 2 Campath-1H;Cyclophosphamide;Busulfan;Cyclosporine A;Mycophenolate Mofetil
14 Autologous Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy Recruiting NCT02559830 Phase 1, Phase 2
15 Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases Recruiting NCT03367546 Phase 2
16 MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis Recruiting NCT02171104 Phase 2 IMD Preparative Regimen;Osteopetrosis Only Preparative Regimen;Osteopetrosis Haploidentical Only Preparative Regimen;cALD SR-A (Standard-Risk, Regimen A);cALD SR-B (Standard-Risk, Regimen B);cALD HR-D (High-Risk, Regimen C);cALD HR-D (High-Risk, Regimen D)
17 Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation Recruiting NCT03513328 Phase 1, Phase 2 Thiotepa--single daily dose;Thiotepa--escalated dose
18 MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT) Recruiting NCT03406962 Phase 2 MGTA-456
19 Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT Recruiting NCT01962415 Phase 2 Hydroxyurea;Alemtuzumab;Fludarabine;Melphalan;Thiotepa
20 Effect of Pioglitazone Administered to Patients With Adrenomyeloneuropathy Active, not recruiting NCT03864523 Phase 2 Pioglitazone
21 Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders Active, not recruiting NCT01372228 Phase 1, Phase 2
22 Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy Withdrawn NCT03196765 Phase 1, Phase 2 Sobetirome (NV1205)
23 A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 After Intravenous Administration in Healthy Volunteers Completed NCT03500627 Phase 1 OP-101
24 A Pilot Study of Vitamin D in Boys With X-linked Adrenoleukodystrophy Recruiting NCT02595489 Phase 1
25 UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells Recruiting NCT02254863 Phase 1
26 Human Placental-Derived Stem Cell Transplantation Active, not recruiting NCT01586455 Phase 1 Human Placental Derived Stem Cell
27 MT2014-14 IT-MSC for Advanced Cerebral Adrenoleukodystrophy (cALD) Withdrawn NCT02410239 Phase 1
28 Safety and Pharmacodynamic Study of Sobetirome in X-Linked Adrenoleukodystrophy (X-ALD) Withdrawn NCT01787578 Phase 1 Sobetirome
29 Clinical Study and Gene Mutation Analysis of Adrenoleukodystrophy in Taiwanese Children Unknown status NCT00278044 Not Applicable
30 Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Unknown status NCT00005900
31 Newborn Screening for Adrenoleukodystrophy Completed NCT02952482
32 The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD) Completed NCT01165060 Not Applicable Bezafibrate
33 Exercise Study of Function and Pathology for Women With X-linked Adrenoleukodystrophy Completed NCT01594853 Not Applicable
34 Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy Completed NCT00004450 Not Applicable glyceryl trierucate;glyceryl trioleate;interferon beta;thalidomide
35 Repetitive Transcranial Magnetic Stimulation as Therapy in Hereditary Spastic Paraplegia and Adrenomyeloneuropathy Completed NCT03627416 Not Applicable
36 Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders Completed NCT01626092 Not Applicable Campath-1H;Clofarabine;Melphalan;Cyclosporine A;Mycophenolate mofetil
37 Lentiviral Gene Therapy for X-ALD Recruiting NCT03727555 Not Applicable
38 A Study to Prospectively Assess Disease Progression in Male Children With X-ALD Recruiting NCT03278899
39 Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD) Recruiting NCT02204904
40 Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants Available NCT01881334
41 Long-term Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product Enrolling by invitation NCT02698579
42 Minnesota Adrenoleukodystrophy Registry Study (MARS) and Biobank Not yet recruiting NCT03789721
43 Multi-center Clinical Study on the Diagnosis and Treatment Management of Rare Neurological Disease in Children Not yet recruiting NCT03649919
44 Expanded Access for Lorenzo's Oil (GTO/GTE) in Adrenoleukodystrophy No longer available NCT02233257 Lorenzo's Oil
45 Study of Bile Acids in Patients With Peroxisomal Disorders Terminated NCT00004442 Not Applicable chenodeoxycholic acid;cholic acid;ursodiol
46 Early Diagnosis Of Childhood Cerebral ALD Withdrawn NCT02948062

Search NIH Clinical Center for Adrenoleukodystrophy

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Adrenoleukodystrophy cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: adrenoleukodystrophy

Genetic Tests for Adrenoleukodystrophy

Genetic tests related to Adrenoleukodystrophy:

# Genetic test Affiliating Genes
1 Adrenoleukodystrophy 30 ABCD1

Anatomical Context for Adrenoleukodystrophy

MalaCards organs/tissues related to Adrenoleukodystrophy:

42
Brain, Cortex, Adrenal Cortex, Adrenal Gland, Skin, Bone, Testes

Publications for Adrenoleukodystrophy

Articles related to Adrenoleukodystrophy:

(show top 50) (show all 1111)
# Title Authors Year
1
Early Onset Primary Adrenal Insufficiency in Males with Adrenoleukodystrophy: Case Series and Literature Review. ( 31101408 )
2019
2
A report on state-wide implementation of newborn screening for X-linked Adrenoleukodystrophy. ( 31074578 )
2019
3
Flow injection ionization-tandem mass spectrometry-based estimation of a panel of lysophosphatidylcholines in dried blood spots for screening of X-linked adrenoleukodystrophy. ( 30980791 )
2019
4
Microglia damage precedes major myelin breakdown in X-linked adrenoleukodystrophy and metachromatic leukodystrophy. ( 30980503 )
2019
5
Thermogenic flux induced by lignoceric acid in peroxisomes isolated from HepG2 cells and from X-adrenoleukodystrophy and control fibroblasts. ( 30932193 )
2019
6
Generation of an induced pluripotent stem cell (iPSC) line from a 42-year-old adult cerebral type X-linked adrenoleukodystrophy (X-ALD) patient. ( 30921588 )
2019
7
Measuring early lesion growth in boys with cerebral demyelinating adrenoleukodystrophy. ( 30902909 )
2019
8
MRI brain lesions in asymptomatic boys with X-linked adrenoleukodystrophy. ( 30902905 )
2019
9
X-linked Adrenoleukodystrophy: Atypical Clinico-Radiological Presentation. ( 30847867 )
2019
10
Cerebral adrenoleukodystrophy is associated with loss of tolerance to profilin. ( 30829395 )
2019
11
Exogenous Addition of 25-Hydroxycholesterol Reduces Level of Very Long-Chain Fatty Acids in X-Linked Adrenoleukodystrophy. ( 30788208 )
2019
12
Broadening the Spectrum of Adulthood X-Linked Adrenoleukodystrophy: A Report of Two Atypical Cases. ( 30787906 )
2019
13
CRISPR/Cas9-mediated knockout of Abcd1 and Abcd2 genes in BV-2 cells: Novel microglial models for X-linked Adrenoleukodystrophy. ( 30769094 )
2019
14
Allogeneic hematopoietic stem cell transplantation with myeloablative conditioning for adult cerebral X-linked adrenoleukodystrophy. ( 30746707 )
2019
15
Disease progression in women with X-linked adrenoleukodystrophy is slow. ( 30732635 )
2019
16
X-linked adrenoleukodystrophy presenting as isolated spastic paraparesia. ( 30697666 )
2019
17
Late onset adrenoleukodystrophy: A review related clinical case report. ( 30671550 )
2019
18
Targeted gene approach with biochemical assay confirms ABCD1 mutation of X-linked adrenoleukodystrophy in a 62-year-old man with gait imbalance. ( 30658899 )
2019
19
Successful donor engraftment and repair of the blood brain barrier in cerebral adrenoleukodystrophy. ( 30635285 )
2019
20
Progression of myelopathy in males with adrenoleukodystrophy: towards clinical trial readiness. ( 30535170 )
2019
21
Allogeneic stem cell transplantation with reduced intensity conditioning for patients with adrenoleukodystrophy. ( 30519529 )
2019
22
Integrative lipidomic and transcriptomic analysis of X-linked adrenoleukodystrophy reveals distinct lipidome signatures between adrenomyeloneuropathy and childhood cerebral adrenoleukodystrophy. ( 30509496 )
2019
23
Perioperative management of a female diagnosed with heterozygous X-linked adrenoleukodystrophy scheduled for shoulder arthroscopy. ( 30447897 )
2019
24
A novel missense mutation in the ABCD1 gene of a Chinese boy diagnosed with X-linked adrenoleukodystrophy: case report. ( 30343438 )
2019
25
Survival and Functional Outcomes in Boys with Cerebral Adrenoleukodystrophy with and without Hematopoietic Stem Cell Transplantation. ( 30292747 )
2019
26
The Natural History of Adrenal Insufficiency in X-Linked Adrenoleukodystrophy: An International Collaboration. ( 30252065 )
2019
27
Characteristics of Japanese patients with X-linked adrenoleukodystrophy and concerns of their families from the 1st registry system. ( 30077509 )
2019
28
Stability of the ABCD1 Protein with a Missense Mutation: A Novel Approach to Finding Therapeutic Compounds for X-Linked Adrenoleukodystrophy. ( 29926352 )
2019
29
Heat shock protein expression in cerebral X-linked adrenoleukodystrophy reveals astrocyte stress prior to myelin loss. ( 28319253 )
2018
30
Potential Risks to Stable Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Children With Cerebral X-linked Adrenoleukodystrophy. ( 30646031 )
2018
31
Case report of dysregulation of primary bile acid synthesis in a family with X-linked adrenoleukodystrophy. ( 30544401 )
2018
32
Childhood cerebral X-linked adrenoleukodystrophy with atypical neuroimaging abnormalities and a novel mutation. ( 29386416 )
2018
33
Gene Therapy for Cerebral Adrenoleukodystrophy. ( 29385368 )
2018
34
Haploidentical bone marrow transplantation with post transplant cyclophosphamide for patients with X-linked adrenoleukodystrophy: a suitable choice in an urgent situation. ( 29330393 )
2018
35
Autonomic dysfunction in a patient with X-linked adrenoleukodystrophy. ( 29284317 )
2018
36
Psychiatric disease in an adolescent as a harbinger of cerebral X-linked adrenoleukodystrophy. ( 29175874 )
2018
37
A novel temporal pattern of childhood cerebral X-linked adrenoleukodystrophy. ( 29132975 )
2018
38
Intrathecal baclofen treatment an option in X-linked adrenoleukodystrophy. ( 28964670 )
2018
39
Quality of life among boys with adrenoleukodystrophy following hematopoietic stem cell transplant. ( 28934891 )
2018
40
Inflammatory profile in X-linked adrenoleukodystrophy patients: Understanding disease progression. ( 28722826 )
2018
41
Economic impact of screening for X-linked Adrenoleukodystrophy within a newborn blood spot screening programme. ( 30309370 )
2018
42
Adrenoleukodystrophy: Guidance for Adrenal Surveillance in Males Identified by Newborn Screen. ( 30289543 )
2018
43
Anaesthetic management of a child with adrenoleukodystrophy: A case report. ( 30166663 )
2018
44
Dendrimer-N-acetyl-L-cysteine modulates monophagocytic response in adrenoleukodystrophy. ( 30069915 )
2018
45
Liquid chromatography-tandem mass spectrometry method for estimation of a panel of lysophosphatidylcholines in dried blood spots for screening of X-linked adrenoleukodystrophy. ( 30018013 )
2018
46
Aberrant regulation of the GSK-3β/NRF2 axis unveils a novel therapy for adrenoleukodystrophy. ( 29997171 )
2018
47
Rare variability in adrenoleukodystrophy: a case report. ( 29950168 )
2018
48
Newborn Screening and Emerging Therapies for X-Linked Adrenoleukodystrophy. ( 29946687 )
2018
49
Late-diagnosed phenylketonuria mimicking x-linked adrenoleukodystrophy with heterozygous mutations of the PAH Gene: A case report and literature review. ( 29909188 )
2018
50
Impaired plasticity of macrophages in X-linked adrenoleukodystrophy. ( 29860501 )
2018

Variations for Adrenoleukodystrophy

UniProtKB/Swiss-Prot genetic disease variations for Adrenoleukodystrophy:

76 (show top 50) (show all 138)
# Symbol AA change Variation ID SNP ID
1 ABCD1 p.Ser98Leu VAR_000024
2 ABCD1 p.Arg104Cys VAR_000025
3 ABCD1 p.Arg104His VAR_000026
4 ABCD1 p.Thr105Ile VAR_000027
5 ABCD1 p.Leu107Pro VAR_000028
6 ABCD1 p.Ser108Trp VAR_000029
7 ABCD1 p.Gly116Arg VAR_000030 rs398123110
8 ABCD1 p.Ala141Thr VAR_000033 rs193922097
9 ABCD1 p.Asn148Ser VAR_000034 rs128624216
10 ABCD1 p.Ser149Asn VAR_000035
11 ABCD1 p.Arg152Cys VAR_000036
12 ABCD1 p.Arg152Pro VAR_000037
13 ABCD1 p.Arg163His VAR_000038 rs105751795
14 ABCD1 p.Tyr174Asp VAR_000039 rs128624217
15 ABCD1 p.Tyr174Ser VAR_000040
16 ABCD1 p.Gln178Glu VAR_000041
17 ABCD1 p.Tyr181Cys VAR_000042
18 ABCD1 p.Arg182Pro VAR_000043
19 ABCD1 p.Asp194His VAR_000044
20 ABCD1 p.Asp200Val VAR_000045
21 ABCD1 p.Leu211Pro VAR_000046
22 ABCD1 p.Leu220Pro VAR_000047
23 ABCD1 p.Asp221Gly VAR_000048
24 ABCD1 p.Thr254Met VAR_000049 rs113169174
25 ABCD1 p.Thr254Pro VAR_000050
26 ABCD1 p.Pro263Leu VAR_000051
27 ABCD1 p.Gly266Arg VAR_000052 rs128624218
28 ABCD1 p.Lys276Glu VAR_000053
29 ABCD1 p.Gly277Arg VAR_000054
30 ABCD1 p.Gly277Trp VAR_000056
31 ABCD1 p.Glu291Asp VAR_000057
32 ABCD1 p.Glu291Lys VAR_000058 rs128624213
33 ABCD1 p.Ala294Thr VAR_000060 rs113169195
34 ABCD1 p.Ser342Pro VAR_000061
35 ABCD1 p.Arg389Gly VAR_000062 rs128624215
36 ABCD1 p.Arg389His VAR_000063 rs886044777
37 ABCD1 p.Arg401Gln VAR_000064 rs128624219
38 ABCD1 p.Arg418Trp VAR_000065 rs128624220
39 ABCD1 p.Pro484Arg VAR_000066 rs128624214
40 ABCD1 p.Gly507Val VAR_000067
41 ABCD1 p.Gly512Ser VAR_000068
42 ABCD1 p.Ser515Phe VAR_000069 rs128624223
43 ABCD1 p.Arg518Gln VAR_000070 rs398123102
44 ABCD1 p.Arg518Trp VAR_000071 rs128624224
45 ABCD1 p.Gly522Trp VAR_000072
46 ABCD1 p.Pro534Leu VAR_000074
47 ABCD1 p.Pro560Leu VAR_000075 rs398123105
48 ABCD1 p.Pro560Arg VAR_000076
49 ABCD1 p.Met566Lys VAR_000077
50 ABCD1 p.Arg591Gln VAR_000078

ClinVar genetic disease variations for Adrenoleukodystrophy:

6 (show top 50) (show all 340)
# Gene Variation Type Significance SNP ID Assembly Location
1 ABCD1 NM_000033.3(ABCD1): c.1252C> T (p.Arg418Trp) single nucleotide variant Pathogenic/Likely pathogenic rs128624220 GRCh37 Chromosome X, 153001826: 153001826
2 ABCD1 NM_000033.3(ABCD1): c.1825G> A (p.Glu609Lys) single nucleotide variant Pathogenic rs150346282 GRCh37 Chromosome X, 153008485: 153008485
3 ABCD1 NM_000033.3(ABCD1): c.1825G> A (p.Glu609Lys) single nucleotide variant Pathogenic rs150346282 GRCh38 Chromosome X, 153743031: 153743031
4 ABCD1 NM_000033.3(ABCD1): c.1533C> G (p.Cys511Trp) single nucleotide variant Uncertain significance rs782370364 GRCh38 Chromosome X, 153740136: 153740136
5 ABCD1 NM_000033.3(ABCD1): c.1998_1999insGC (p.His667Alafs) insertion Likely pathogenic rs1557055392 GRCh38 Chromosome X, 153743495: 153743496
6 ABCD1 NM_000033.3(ABCD1): c.1998_1999insGC (p.His667Alafs) insertion Likely pathogenic rs1557055392 GRCh37 Chromosome X, 153008949: 153008950
7 ABCD1 NM_000033.3(ABCD1): c.1599G> T (p.Lys533Asn) single nucleotide variant Uncertain significance GRCh38 Chromosome X, 153740202: 153740202
8 ABCD1 NM_000033.3(ABCD1): c.1660dup (p.Arg554Profs) duplication Pathogenic GRCh38 Chromosome X, 153740599: 153740599
9 ABCD1; BCAP31; PLXNB3 GRCh37/hg19 Xq28(chrX: 152980470-153032459) copy number loss Pathogenic GRCh37 Chromosome X, 152980470: 153032459
10 ABCD1 NM_000033.4(ABCD1): c.2010dup (p.Leu671Alafs) duplication Likely pathogenic GRCh38 Chromosome X, 153743507: 153743507
11 ABCD1 NM_000033.4(ABCD1): c.2010dup (p.Leu671Alafs) duplication Likely pathogenic GRCh37 Chromosome X, 153008961: 153008962
12 ABCD1 NM_000033.4(ABCD1): c.1973C> T (p.Thr658Ile) single nucleotide variant Likely pathogenic GRCh37 Chromosome X, 153008782: 153008782
13 ABCD1 NM_000033.4(ABCD1): c.1973C> T (p.Thr658Ile) single nucleotide variant Likely pathogenic GRCh38 Chromosome X, 153743328: 153743328
14 ABCD1 NM_000033.4(ABCD1): c.1597A> C (p.Lys533Gln) single nucleotide variant Likely pathogenic GRCh37 Chromosome X, 153005654: 153005654
15 ABCD1 NM_000033.4(ABCD1): c.1597A> C (p.Lys533Gln) single nucleotide variant Likely pathogenic GRCh38 Chromosome X, 153740200: 153740200
16 ABCD1 NM_000033.4(ABCD1): c.1186G> A (p.Ala396Thr) single nucleotide variant Likely pathogenic GRCh37 Chromosome X, 153001670: 153001670
17 ABCD1 NM_000033.4(ABCD1): c.1186G> A (p.Ala396Thr) single nucleotide variant Likely pathogenic GRCh38 Chromosome X, 153736216: 153736216
18 ABCD1 NM_000033.4(ABCD1): c.1165C> T (p.Arg389Cys) single nucleotide variant Likely pathogenic GRCh37 Chromosome X, 153001649: 153001649
19 ABCD1 NM_000033.4(ABCD1): c.1165C> T (p.Arg389Cys) single nucleotide variant Likely pathogenic GRCh38 Chromosome X, 153736195: 153736195
20 ABCD1 NM_000033.4(ABCD1): c.593C> T (p.Thr198Met) single nucleotide variant Likely pathogenic GRCh37 Chromosome X, 152991314: 152991314
21 ABCD1 NM_000033.4(ABCD1): c.593C> T (p.Thr198Met) single nucleotide variant Likely pathogenic GRCh38 Chromosome X, 153725859: 153725859
22 ABCD1 NM_000033.4(ABCD1): c.487C> T (p.Arg163Cys) single nucleotide variant Likely pathogenic GRCh37 Chromosome X, 152991208: 152991208
23 ABCD1 NM_000033.4(ABCD1): c.487C> T (p.Arg163Cys) single nucleotide variant Likely pathogenic GRCh38 Chromosome X, 153725753: 153725753
24 ABCD1 NM_000033.4(ABCD1): c.80A> C (p.Tyr27Ser) single nucleotide variant Likely pathogenic GRCh37 Chromosome X, 152990801: 152990801
25 ABCD1 NM_000033.4(ABCD1): c.80A> C (p.Tyr27Ser) single nucleotide variant Likely pathogenic GRCh38 Chromosome X, 153725346: 153725346
26 ABCD1 NM_000033.4(ABCD1): c.1225-7_1239del deletion Pathogenic GRCh37 Chromosome X, 153001792: 153001813
27 ABCD1 NM_000033.4(ABCD1): c.1225-7_1239del deletion Pathogenic GRCh38 Chromosome X, 153736338: 153736359
28 ABCD1 NM_000033.4(ABCD1): c.595G> A (p.Glu199Lys) single nucleotide variant Uncertain significance GRCh37 Chromosome X, 152991316: 152991316
29 ABCD1 NM_000033.4(ABCD1): c.595G> A (p.Glu199Lys) single nucleotide variant Uncertain significance GRCh38 Chromosome X, 153725861: 153725861
30 ABCD1 NM_000033.4(ABCD1): c.320T> C (p.Leu107Pro) single nucleotide variant Likely pathogenic GRCh38 Chromosome X, 153725586: 153725586
31 ABCD1 NM_000033.4(ABCD1): c.320T> C (p.Leu107Pro) single nucleotide variant Likely pathogenic GRCh37 Chromosome X, 152991041: 152991041
32 ABCD1 NM_000033.3(ABCD1): c.1978C> T (p.Arg660Trp) single nucleotide variant Pathogenic GRCh37 Chromosome X, 153008787: 153008787
33 ABCD1 NM_000033.3(ABCD1): c.1978C> T (p.Arg660Trp) single nucleotide variant Pathogenic GRCh38 Chromosome X, 153743333: 153743333
34 ABCD1 NM_000033.3(ABCD1): c.1534G> A (p.Gly512Ser) single nucleotide variant Pathogenic GRCh37 Chromosome X, 153005591: 153005591
35 ABCD1 NM_000033.3(ABCD1): c.1534G> A (p.Gly512Ser) single nucleotide variant Pathogenic GRCh38 Chromosome X, 153740137: 153740137
36 ABCD1 NM_000033.3(ABCD1): c.1096A> T (p.Lys366Ter) single nucleotide variant Pathogenic GRCh38 Chromosome X, 153736126: 153736126
37 ABCD1 NM_000033.3(ABCD1): c.1096A> T (p.Lys366Ter) single nucleotide variant Pathogenic GRCh37 Chromosome X, 153001580: 153001580
38 ABCD1 NM_000033.3(ABCD1): c.1866-1G> A single nucleotide variant Likely pathogenic GRCh38 Chromosome X, 153743220: 153743220
39 ABCD1 NM_000033.3(ABCD1): c.1866-1G> A single nucleotide variant Likely pathogenic GRCh37 Chromosome X, 153008674: 153008674
40 ABCD1 NM_000033.3(ABCD1): c.1747G> A (p.Val583Met) single nucleotide variant Uncertain significance GRCh38 Chromosome X, 153740686: 153740686
41 ABCD1 NM_000033.3(ABCD1): c.1747G> A (p.Val583Met) single nucleotide variant Uncertain significance GRCh37 Chromosome X, 153006140: 153006140
42 ABCD1 NM_000033.3(ABCD1): c.1644G> A (p.Met548Ile) single nucleotide variant Uncertain significance GRCh38 Chromosome X, 153740583: 153740583
43 ABCD1 NM_000033.3(ABCD1): c.1644G> A (p.Met548Ile) single nucleotide variant Uncertain significance GRCh37 Chromosome X, 153006037: 153006037
44 ABCD1 NM_000033.3(ABCD1): c.638C> A (p.Ser213Tyr) single nucleotide variant Uncertain significance GRCh38 Chromosome X, 153725904: 153725904
45 ABCD1 NM_000033.3(ABCD1): c.638C> A (p.Ser213Tyr) single nucleotide variant Uncertain significance GRCh37 Chromosome X, 152991359: 152991359
46 ABCD1 NM_000033.3(ABCD1): c.582C> G (p.Asp194Glu) single nucleotide variant Uncertain significance GRCh38 Chromosome X, 153725848: 153725848
47 ABCD1 NM_000033.3(ABCD1): c.582C> G (p.Asp194Glu) single nucleotide variant Uncertain significance GRCh37 Chromosome X, 152991303: 152991303
48 ABCD1 NM_000033.3(ABCD1): c.2134C> T (p.Arg712Cys) single nucleotide variant Uncertain significance GRCh38 Chromosome X, 153743631: 153743631
49 ABCD1 NM_000033.3(ABCD1): c.2134C> T (p.Arg712Cys) single nucleotide variant Uncertain significance GRCh37 Chromosome X, 153009085: 153009085
50 ABCD1 NM_000033.3(ABCD1): c.1763T> A (p.Ile588Asn) single nucleotide variant Uncertain significance GRCh37 Chromosome X, 153006156: 153006156

Expression for Adrenoleukodystrophy

Search GEO for disease gene expression data for Adrenoleukodystrophy.

Pathways for Adrenoleukodystrophy

Pathways related to Adrenoleukodystrophy according to KEGG:

38
# Name Kegg Source Accession
1 ABC transporters hsa02010
2 Peroxisome hsa04146

GO Terms for Adrenoleukodystrophy

Cellular components related to Adrenoleukodystrophy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum membrane GO:0005789 9.83 ABCB6 ABCD1 ABCD4 BCAP31 SLC27A2
2 peroxisome GO:0005777 9.8 ABCD1 ABCD2 ABCD3 ABCD4 ACOX1 CAT
3 peroxisomal matrix GO:0005782 9.56 ABCD3 ACOX1 CAT EHHADH
4 integral component of peroxisomal membrane GO:0005779 9.46 ABCD1 PEX10 PEX26 SLC27A2
5 peroxisomal membrane GO:0005778 9.44 ABCD1 ABCD2 ABCD3 ABCD4 ACOX1 CAT
6 ATP-binding cassette (ABC) transporter complex GO:0043190 9.4 ABCB6 ABCD4
7 membrane GO:0016020 10.24 ABCB6 ABCD1 ABCD2 ABCD3 ABCD4 ACOX1
8 cytosol GO:0005829 10.13 ABCB6 ABCD1 ABCD2 ABCD3 ACOX1 BCAP31

Biological processes related to Adrenoleukodystrophy according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 9.95 ABCD1 ABCB6 ABCD2 ABCD3 ABCD4 PEX19
2 fatty acid metabolic process GO:0006631 9.75 ACOX1 EHHADH SLC27A2
3 fatty acid beta-oxidation GO:0006635 9.7 ABCD1 ABCD3 ACOX1 ABCD2 EHHADH PEX5
4 protein import into peroxisome matrix GO:0016558 9.65 PEX1 PEX10 PEX26 PEX5 PEX6
5 protein targeting to peroxisome GO:0006625 9.65 ACOX1 CAT EHHADH PEX1 PEX6 SLC27A2
6 very long-chain fatty acid catabolic process GO:0042760 9.62 ABCD1 ABCD2 ABCD3 SLC27A2
7 fatty acid beta-oxidation using acyl-CoA oxidase GO:0033540 9.58 ABCD1 ACOX1 EHHADH
8 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.57 ABCD1 ABCD2
9 alpha-linolenic acid metabolic process GO:0036109 9.56 ABCD1 ACOX1
10 negative regulation of reactive oxygen species biosynthetic process GO:1903427 9.55 ABCD1 ABCD2
11 very long-chain fatty acid metabolic process GO:0000038 9.54 ABCD2 ACOX1
12 protein import into peroxisome membrane GO:0045046 9.54 PEX19 PEX26 PEX5
13 neuron projection maintenance GO:1990535 9.52 ABCD1 ABCD2
14 positive regulation of fatty acid beta-oxidation GO:0032000 9.51 ABCD1 ABCD2
15 myelin maintenance GO:0043217 9.49 ABCD1 ABCD2
16 peroxisomal long-chain fatty acid import GO:0015910 9.46 ABCD1 ABCD3
17 positive regulation of unsaturated fatty acid biosynthetic process GO:2001280 9.43 ABCD1 ABCD2
18 peroxisome organization GO:0007031 9.17 PEX1 PEX10 ABCD3 ABCD1 PEX19 PEX5

Molecular functions related to Adrenoleukodystrophy according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.86 ABCB6 ABCD1 ABCD2 ABCD3 ABCD4 PEX1
2 nucleotide binding GO:0000166 9.78 ABCB6 ABCD1 ABCD2 SLC27A2
3 signaling receptor binding GO:0005102 9.76 ACOX1 CAT EHHADH SLC27A2
4 enzyme binding GO:0019899 9.72 ABCD1 CAT EHHADH PEX5 SLC27A2
5 protein C-terminus binding GO:0008022 9.67 PEX1 PEX26 PEX6
6 protein-containing complex binding GO:0044877 9.67 BCAP31 PEX1 PEX26 PEX6
7 protein N-terminus binding GO:0047485 9.58 ACOX1 PEX19 PEX5
8 ATPase activity, coupled to transmembrane movement of substances GO:0042626 9.55 ABCB6 ABCD1 ABCD2 ABCD3 ABCD4
9 ATPase activity, coupled GO:0042623 9.43 PEX1 PEX6
10 ATPase activity GO:0016887 9.17 ABCB6 ABCD1 ABCD2 ABCD3 ABCD4 PEX1
11 long-chain fatty acid transporter activity GO:0005324 9.13 ABCD1 ABCD3 SLC27A2

Sources for Adrenoleukodystrophy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....